Buying AOD-9604 in the USA: What the Fragment Label Leaves Out

Cut a piece out of a protein and you do not get a smaller protein. You get a new molecule whose behavior has to be worked out from scratch. AOD-9604 is a clean example of that rule, and of how easily the point gets lost in the way fragments are described.

Where the sequence comes from

Human growth hormone runs to 191 residues. AOD-9604 reproduces the C-terminal stretch of that chain, residues 176 through 191, and prepends a tyrosine at the N-terminus. The extra residue is a designed stabilization rather than a synthesis artifact.

The molecule is usually written as YLRIVQCRSVEGSCGF: sixteen residues in total, the added tyrosine followed by hGH 177 to 191. Counting within that string, cysteines fall at positions seven and fourteen, and those two residues form the intramolecular bridge.

Why it is not a miniature growth hormone

Receptor engagement by hGH depends on a binding surface spread across the folded protein. Sixteen linear residues cannot rebuild that surface, so there is no basis for expecting AOD-9604 to behave as a growth hormone receptor agonist. Published work treats the fragment as mechanistically distinct from the parent hormone, not as a compact substitute for it.

Saying so directly is necessary because catalog copy across this industry frequently suggests the opposite. Indexed references can be pulled from PubMed.

Reading a thin body of work

There is not a great deal published, and what exists is largely preclinical. Results that come from a single model system in a single laboratory are best held as provisional until someone else reproduces them. When a review quotes a striking number, the productive move is to follow it back to the primary paper and look at the model used, the concentration tested and the controls run.

The bridge dictates both buffer choice and storage

Inheriting a disulfide from the parent sequence gives this fragment a constraint that plain linear peptides escape. Reducing agents in solution will open the bridge and leave a different molecule behind, so dithiothreitol and beta-mercaptoethanol cannot be treated as inert additions.

The concern extends well past the reducing agent bottle. Thiol-disulfide exchange proceeds wherever a free thiol exists, and the rate climbs sharply once pH moves above neutral. Residue left in glassware, a buffer component that happens to carry a thiol, or a solution parked at pH 8 for convenience will each shift the equilibrium. With one bridge present, the outcome is a mix of the intended cyclic species and an open reduced chain; in mixtures where several disulfide-bearing species coexist, scrambled products can form that share the mass of the starting material.

Countermeasures are unglamorous and effective: keep the powder dry and sealed until it is needed, reconstitute into a buffer at or just below neutral pH, leave thiol-containing additives out unless the experiment calls for them, and split the stock into aliquots so one vial is not opened over and over. The general cases are covered in our notes on storage and stability and on the origins of peptide impurities.

What a mass measurement is actually comparing

That published sequence is the reference a mass spectrum gets checked against. A certificate ought to carry two figures: a calculated mass for the intended sequence and an observed mass from the instrument. The question worth asking is not whether the observed number looks reasonable in isolation, but whether the pair agree inside the tolerance the method claims. One number on its own gives you nothing to verify.

Mass also separates the reduced form from the oxidized one, which differ by two units – a detail worth confirming for any disulfide-containing peptide. Our discussion of HPLC and mass spectrometry verification goes into the methods.

A side benefit of the N-terminal tyrosine, whatever the original reason for adding it, is analytical. Tyrosine absorbs at 280 nm, so the concentration of a reconstituted solution can be estimated by absorbance instead of being taken on faith from the label. With no tryptophan present and only one tyrosine, that reading is coarse, but it is still an independent check on a figure that otherwise depends entirely on the stated mass in the vial.

Three certificate checks, in priority order

Identity by mass. First, for the reason just given: a two-unit gap between reduced and oxidized forms is small enough that it only turns up when someone goes looking for it.

Purity by HPLC. Second, and the chromatogram matters more than the headline figure. A single sharp peak quoted at 98% and a peak carrying a pronounced shoulder quoted at 98% describe different materials, and the number alone conveys only one of those two facts.

Net peptide content. Third, and most often skipped. Synthetic peptides usually arrive as trifluoroacetate salts, where counter-ion and residual water together can occupy a meaningful share of the vial mass. A vial marked 5 mg holds 5 mg of powder, which is not the same as 5 mg of peptide, and anywhere concentration matters that gap has to be resolved from the certificate rather than assumed away. See our notes on net peptide content and on counter-ions and salt form for how the figures relate.

Product: AOD-9604 5mg, cataloged alongside other growth hormone pathway peptides.

ExoLabz supplies compounds for laboratory research use only. Nothing on this page constitutes medical advice or a suggestion of human or veterinary use. Analytical documentation is published where it is available.